Boston Scientific Corporation [BSX] Securities Class Action Lawsuit Update

• Case Name: Troike v. Boston Scientific Corporation, et al.
• Case No.: 4:26-cv-40075
• Jurisdiction: U.S. District Court, District of Massachusetts
• Filed on: March 5, 2026
• Class Period: July 23, 2025 – February 3, 2026

Introduction

Boston Scientific Corporation told investors it was positioned for differentiated long-term performance and continued growth in its U.S. Electrophysiology business. The complaint alleges those statements were materially misleading.

A federal securities class action filed in the District of Massachusetts, Case No. 4:26-cv-40075, alleges that Boston Scientific Corporation (NYSE: BSX) and several senior executives misled investors about the durability of its U.S. Electrophysiology business between July 23, 2025 and February 3, 2026. According to the complaint, defendants repeatedly expressed confidence in the sustainability of the Company’s U.S. EP growth trajectory, raised guidance during 2025, and then disclosed weaker-than-expected U.S. EP performance and 2026 guidance on February 4, 2026.

On February 4, 2026, Boston Scientific reported disappointing EP performance and issued forward guidance that fell below market expectations. The stock dropped approximately 17.6% in a single day, closing at $75.50 after trading at $91.62 the day prior. The complaint alleges that the February 4, 2026 disclosures revealed that Boston Scientific’s U.S. EP growth was slowing sooner than investors had been led to expect.

“Most BSX shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Boston Scientific is a global medical device company. Its Electrophysiology business develops products used in the detection and treatment of heart rate and rhythm disorders, including the FARAPULSE PFA system.

The EP division focuses on technologies used to diagnose and treat heart rhythm disorders, including its flagship FARAPULSE system. During the Class Period, the company positioned this segment as the fastest-growing component of its portfolio and, more importantly, as a sustained engine of expansion.

During the Class Period, defendants described the EP market as large and fast-growing, emphasized Boston Scientific’s competitive position in pulsed field ablation, and expressed confidence that the Company could continue gaining share and outpacing the market.

Because EP was a major focus of management’s growth messaging, the complaint alleges that weaker-than-expected EP results had an outsized effect on investor reaction.

Promises Made vs. Reality

Throughout the Class Period, defendants made positive statements about Boston Scientific’s U.S. EP growth trajectory, competitive position, and ability to continue gaining share.

In July 2025, CEO Michael Mahoney described “exceptional top-line performance” and raised guidance, reinforcing expectations for continued expansion across key segments, including EP. Subsequent earnings calls, investor presentations, and conference appearances repeated the same themes. The EP business was growing rapidly, supported by technology leadership, increasing physician adoption, and what management described as a well-understood competitive landscape. Executives emphasized their ability to maintain leadership in pulsed field ablation while continuing to expand market share.

They spoke about ecosystem advantages, integrated platforms, and the Company’s expectation that EP demand and market growth would remain strong. The complaint alleges that defendants consistently presented EP growth as sustainable and competitively resilient.

The complaint tells a different version of events. Investors allege that, behind the public statements, Boston Scientific was already facing material headwinds. Procedure volumes were slowing. Competitive entrants were gaining traction. Regulatory and reimbursement dynamics were evolving in ways that constrained growth. The EP market, rather than accelerating indefinitely, was approaching a tipping point earlier than investors were led to believe.

The difference between those two narratives is where the case lives.

Timeline of Alleged Misconduct and Disclosures

The complaint identifies a series of statements between July 2025 and January 2026 that allegedly misled investors about the sustainability of U.S. EP growth.

On July 23, 2025, Boston Scientific reported strong second-quarter results and raised full-year guidance, highlighting continued momentum in EP. On September 30, 2025, at its Investor Day, management reiterated confidence in the long-term growth trajectory of the EP market and the company’s ability to outpace it.

On October 22, 2025, the company again reported strong performance and raised guidance, pointing to continued strength across its cardiovascular businesses. In December 2025, executives addressed competition directly at an investor conference, stating that they had a “very good understanding” of the competitive landscape and its timing.

By January 2026, the tone had not changed. At the JPM Healthcare Conference, management continued to describe EP and related products as differentiated growth drivers, reinforcing investor expectations for continued expansion.

Then, on February 4, 2026, the company released its fourth-quarter and full-year results. The data told a different story. EP performance disappointed. Growth slowed. Forward guidance for 2026 came in below expectations. Management acknowledged slower market growth and increasing competition, including the impact of new entrants and share loss. The market reaction was immediate. The stock declined sharply in a single trading session, reflecting a rapid repricing of expectations.

Investor Harm and Market Reaction

Markets do not just react to numbers. They react to broken narratives.

Following the February 2026 disclosure, analysts recalibrated quickly. Raymond James noted that the deceleration in the U.S. EP franchise occurred earlier than expected, prompting a reduction in estimates and price targets. Barclays pointed to EP sales missing consensus expectations and highlighted weaker-than-anticipated guidance for 2026.

Evercore removed Boston Scientific from a tactical positioning list, acknowledging that the investment thesis had not played out as anticipated. The throughline across these reactions was consistent. EP had been a primary driver of growth. Its slowdown had disproportionate consequences.

Investors who purchased shares during the Class Period allege that the stock traded at artificially inflated levels, reflecting a growth trajectory that was not sustainable under the conditions that actually existed.

Litigation and Procedural Posture

The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, alleging that Boston Scientific and its executives made materially false and misleading statements or omissions.

The defendants include the company itself and several senior executives, including CEO Michael F. Mahoney and CFO Jonathan R. Monson, along with other leadership figures tied to the EP segment.

The allegations focus on scienter, the idea that defendants knew, or were reckless in not knowing, that their statements were misleading. According to the complaint, executives had access to internal data reflecting slowing growth and competitive pressures but continued to issue optimistic projections and reassurances.

The complaint asserts claims under Sections 10(b) and 20(a) and Rule 10b-5 based on alleged materially false and misleading statements and omissions.

Shareholder Sentiment

Following Boston Scientific’s February 4, 2026 disclosure, investor sentiment across social media and retail forums shifted from largely optimistic to more cautious.

Earlier discussion often emphasized confidence in the Company’s Electrophysiology growth story, particularly its positioning in pulsed field ablation. After the disclosure, however, commentary focused on weaker-than-expected U.S. EP performance and a softer outlook, with investors questioning whether growth had peaked sooner than expected.

The shift in tone reflected broader concerns around competition, growth sustainability, and forward visibility.

Analyst Commentary

Analyst coverage similarly turned more cautious following Boston Scientific’s February 4, 2026 results and guidance.

During the Class Period, coverage highlighted the Company’s strong positioning in Electrophysiology and its role as a key growth driver. After the disclosure, analysts focused on the unexpected slowdown in U.S. EP sales and guidance that fell below expectations.

Commentary pointed to earlier-than-anticipated deceleration and increasing competitive pressures, leading to a more measured outlook on near-term growth.

SEC Filings & Risk Factors

Boston Scientific’s public SEC filings, including its periodic reports and earnings disclosures, contained risk factors typical of the medical device industry. These included references to competition, regulatory approvals, reimbursement dynamics, and market adoption rates.

The complaint, however, alleges that these generalized disclosures were insufficient in light of the specific risks the company was facing during the Class Period. Investors argue that the company failed to disclose the extent to which competitive entrants and slowing market growth were already impacting the EP segment.

In securities litigation, the distinction between disclosed risk and concealed reality is often central. A risk that is framed as hypothetical but is already materializing can become the basis for liability.

That is the tension at the core of this case.

Conclusion: Implications for Investors

The complaint alleges that Boston Scientific presented its U.S. EP business as a durable growth driver while omitting information about slowing growth and increasing competition. The litigation will address whether those alleged statements and omissions were materially misleading under the federal securities laws.

How to Join the Boston Scientific Corporation (BSX) Class Action

• Confirm you purchased BSX shares during the relevant Class Period
• Review eligibility details to determine if your losses qualify
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.